Abbott Announces New Positive Data From REFLECT Studies Of FreeStyle Libre CGM
(RTTNews) - Abbott Laboratories (ABT) Thursday announced positive data from REFLECT studies of its FreeStyle Libre continuous glucose monitoring (CGM) technology.
The REFLECT studies, funded by Abbott, were real-world retrospective studies conducted using data from the Swedish National Diabetes Register (NDR).
New results from the study showed that use of Libre technology reduced cardiovascular disease-related hospitalizations by 78% for people living with Type 1 diabetes with prior severe low blood sugar episodes. Findings from the studies also show a similar reduction in heart-related hospitalizations for those with Type 2 diabetes on insulin using Libre biowearable technology.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.